Cart
sales@molnova.com
RKI-1447
CAS No. 1342278-01-6
RKI-1447( RKI-1447 | RKI1447 | RKI 1447. ROCK Inhibitor XIII )
Catalog No. M11372 CAS No. 1342278-01-6
RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 49 | In Stock |
|
| 5MG | 45 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 25MG | 187 | In Stock |
|
| 50MG | 305 | In Stock |
|
| 100MG | 405 | In Stock |
|
| 200MG | 510 | In Stock |
|
| 500MG | 823 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRKI-1447
-
NoteResearch use only, not for human use.
-
Brief DescriptionRKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.
-
DescriptionRKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.(In Vitro):RKI-1447 is a Type I kinase inhibitor that binds the ATP binding site through interactions with the hinge region and the DFG motif. RKI-1447 suppresses phosphorylation of the ROCK substrates mLC-2 and MYPT-1 in human cancer cells, but has no effect on the phosphorylation levels of the AKT, MEK and S6 kinase at concentrations as high as 10 μM. RKI-1447 is also highly selective at inhibiting ROCK-mediated cytoskeleton re-organization. RKI-1447 inhibits migration, invasion and anchorage-independent tumor growth of breast cancer cells.(In Vivo):RKI-1447 is highly effective at inhibiting the outgrowth of mammary tumors in a transgenic mouse model. RKI-1447 inhibits mammary tumor growth by 87% and on average the mammary tumors from RKI-1447 treated mice are 7.7 fold smaller compared to those tumors from mice treated with the vehicle control.
-
In VitroRKI-1447 is a Type I kinase inhibitor that binds the ATP binding site through interactions with the hinge region and the DFG motif. RKI-1447 suppresses phosphorylation of the ROCK substrates mLC-2 and MYPT-1 in human cancer cells, but has no effect on the phosphorylation levels of the AKT, MEK and S6 kinase at concentrations as high as 10 μM. RKI-1447 is also highly selective at inhibiting ROCK-mediated cytoskeleton re-organization. RKI-1447 inhibits migration, invasion and anchorage-independent tumor growth of breast cancer cells.
-
In VivoRKI-1447 is highly effective at inhibiting the outgrowth of mammary tumors in a transgenic mouse model. RKI-1447 inhibits mammary tumor growth by 87% and on average the mammary tumors from RKI-1447 treated mice are 7.7 fold smaller compared to those tumors from mice treated with the vehicle control.
-
SynonymsRKI-1447 | RKI1447 | RKI 1447. ROCK Inhibitor XIII
-
PathwayCell Cycle/DNA Damage
-
TargetROCK
-
RecptorROCK1| ROCK2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1342278-01-6
-
Formula Weight326.37
-
Molecular FormulaC16H14N4O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 65 mg/mL (199.16 mM)
-
SMILESO=C(NC1=NC(C2=CC=NC=C2)=CS1)NCC3=CC=CC(O)=C3
-
Chemical Name1-(3-Hydroxybenzyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Patel RA, et al. Y Res, 2012, 72(19), 5025-5034.
molnova catalog
related products
-
AS 1892802
AS 1892802 is a potent and selective inhibitor of ROCK. AS 1892802 exibits IC50 values of 52nM, 57nM and 122 nM for human ROCK2, rat ROCK2 and human ROCK1, respectively.
-
BDP5290
BDP5290 is a potent inhibitor of both ROCK and MRCK(IC50s of 5 nM 50 nM 10 nM and 100 nM for ROCK1 ROCK2 MRCKα and MRCKβ respectively.)
-
RKI-1313
RKI-1313 was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion.
